An experimental drug is showing potential for treating Crohn’s disease.
The experimental drug mongersen produced clinical remission in nearly half of patients with Crohn’s disease after 12 weeks of treatment, and an endoscopic response in 37% of those who received the oral agent, according to a study presented at the 2016 United European Gastroenterology Week (abstract LB16).
Gary Lichtenstein, MD, director of the Inflammatory Bowel Disease Center at the Hospital of the University of Pennsylvania, in Philadelphia, who was not involved in the research, called the outcomes “impressive.”
“These results are not definitive, because the study was small and the follow-up period was short, but they are very promising,” said Dr. Lichtenstein, who also is professor of medicine at Penn’s Raymond and Ruth Perelman School of Medicine. “The question will be whether ongoing treatment maintains remission and response.”
|Read Full Article: ‘Impressive’ Efficacy for New Oral Agent in Crohn’s Disease – Gastroenterology & Endoscopy News|